Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
SystImmune’s IND for BL-M11D1 in Relapsed AML Cleared by FDA
Details : BL-M11D1, an ADC comprising a monoclonal antibody component binding CD33 and a linker-payload component. It is being evaluated for the treatment of r/r Acute Myeloid Leukemia.
Product Name : BL-M11D1
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 14, 2024
SystImmune Announces FDA IND Clearance for BL-M17D1 in Solid Tumors
Details : BL-M17D1 is an antibody-drug conjugate with a novel linker and payload technology, which is currently being evaluated for the treatment of patients with advanced or metastatic solid tumors.
Product Name : BL-M17D1
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 11, 2024
Details : BL-B01D1 is a first-in-class bispecific antibody-drug conjugate (ADC) developed by SystImmune, targeting both EGFR and HER3, proteins that are highly expressed in most epithelial tumors in individuals with Metastatic or Unresectable Non-Small Cell Lung C...
Product Name : BL-B01D1
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 10, 2023
Details : Under the collaboration, SystImmune and Bristol Myers Squibb will co-develop and co-commercialize BL-B01D1, a potentially first-in-class bispecific EGFRxHER3 ADC with potential to treat patients with lung and breast cancer, in the United States.
Product Name : BL-B01D1
Product Type : Other Large Molecule
Upfront Cash : $800.0 million
November 12, 2023
Lead Product(s) : BL-B01D1,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BL-B01D1 is a first-in-class bispecific antibody-drug conjugate developed by SystImmune, targeting both EGFR and HER3, proteins that are highly expressed in most epithelial tumors.
Product Name : BL-B01D1
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
January 07, 2023
Lead Product(s) : BL-B01D1,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable